Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoCroS: Adalimumab in Crohn's Disease
NCT03917303Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in Crohn's disease (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Number of yearly-quarters of corticosteroid free remission at 96 weeks. Started Dec 2019; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03917303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917303.